men revealed intra-axonal polyglucosan bodies that confirmed the clinical diagnosis. Bulbar and limb weakness progressed, and she developed dementia. She died 6 years after onset. At autopsy, extensive polyglucosan body formation was found in many regions of the central nervous system. In addition, numerous ␣-synuclein staining Lewy bodies were observed in the substantia nigra, accompanied by marked neuron depopulation.
Conclusions: To our knowledge, this is the first report of adult PGBD associated with Lewy bodies and levodoparesponsive tremor. Although polyglucosan bodies were seen in substantia nigra, it is most likely that our patient had coexisting Parkinson disease.
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A DULT POLYGLUCOSAN body disease (PGBD) was first described in 1980 and is a rare, progressive neurologic disorder. It is characterized by the presence of intra-axonal polyglucosan bodies in the central and peripheral nervous system. Patients usually present in the fifth or sixth decade of life with upper and lower motor neuron involvement, neurogenic bladder and, in some cases, dementia. Extrapyramidal features are rare. We describe a woman with PGBD who was seen with a resting tremor in the lower limbs that responded to levodopa therapy. Over the next 2 years upper and lower motor neuron dysfunction, urinary incontinence, and dementia developed. Sural nerve biopsy findings confirmed PGBD. Her condition progressed to death 6 years after onset. Autopsy showed typical histological features of PGBD as well as Lewy body formation in the substantia nigra.
REPORT OF A CASE
A 46-year-old woman who had a 4-year history of resting tremor affecting both feet was examined at our institution. Therapy with pergolide mesylate was started at doses up to 6.5 mg/d without significant improvement. When we first saw her, she had severe bilateral tremor, symmetrically slowed limb movements, slowed gait with mild postural instability, dysarthria, and limb hypertonia that was greater on the left side. Other examination findings included left hand weakness, left arm hyperreflexia, and a positive Babinski sign on the left side.
A combination of levodopa, 25 mg, and carbidopa, 100 mg, was taken 3 times daily and gradually titrated upward to a levodopa dose of 300 mg, 3 times daily. At this dose, she noted complete remission of foot tremor but developed involuntary twisting movements of her feet consistent with levodopa-induced dyskinesias. Levodopa dosing was reduced with resolution of the dyskinesias and continued efficacy for tremor. The foot tremor recurred if the time between levodopa doses exceeded 5 hours.
During the next 6 months weakness spread to involve all 4 limbs. She developed urinary incontinence and worsening dysarthria and dysphagia. There was no history of sensory involvement, memory deficit, or toxin exposure. Family history was unremarkable. There was no known consanguinity, nor was she of Ashkenazi Jewish descent. On a second physical examination, the patient's mental status was normal. She had spastic dysarthria. Fasciculations were present in limb muscles and possibly the tongue. Mild atrophy was noted in intrinsic hand muscles. Bradykinesia was prominent. She had mild facial and neck weakness. Asymmetric moderate distal (Medical Research Council grade 3-4) greater than proximal limb weakness affected all limbs. She had marked spasticity in all limbs, and gait was spastic. Deep tendon reflexes were diffusely brisk. Bilateral Hoffmann signs and extensor plantar responses were elicited. Sensation to all modalities was spared.
Complete blood cell count and routine blood chemistry findings were normal. Further laboratory results were normal or negative including erythrocyte sedimentation rate, antinuclear antibody level, rheumatoid factor, SSA/ anti-Ro, SSB/anti-La, serum copper level, ceruloplasmin level, phytanic acid level, hexosaminidase A level, lactate level, vitamin E and B 12 levels, and serologic tests for syphilis and Lyme disease. Cerebrospinal fluid analysis findings were also normal. Magnetic resonance imaging of the brain revealed nonspecific foci of increased signal in subcortical white matter interpreted as microvascular ischemia. Magnetic resonance imaging of the spine was normal. Sensory and motor nerve conduction study results were normal. Needle electromyography revealed changes of diffuse chronic denervation with reinnervation. Fibrillation potentials were limited to bilateral hand muscles. Visual evoked responses were normal.
Sections of the sural nerve biopsy specimen revealed a slight loss of myelinated fibers, with no selective fascicular degeneration. Several myelinated fibers contained rounded, periodic acid-Schiff(PAS)-positive intra-axonal inclusions that, in toluidine blue-stained plastic sections, appeared as lightly metachromatic, concentrically laminated structures (Figure 1) . Ultrastructurally, the deposits comprised randomly positioned filaments measuring 6.5 to 10.5 nm in diameter, typical of polyglucosan bodies (Figure 1) . Gastrocnemius sections revealed evidence of denervation atrophy, manifested by the presence of angular atrophic fibers highlighted by esterase and nicotinamide adenine dinucleotide-tetrazolium reductase stains, occasional target fibers, and well-developed fiber-type grouping. No PAS-positive deposits were present in muscle to suggest type IV glycogenosis.
Bulbar and limb weakness progressed so that she became wheelchair bound and required a feeding tube. Dementia also developed. The tremor, however, continued to respond to levodopa. She died 6 years after onset. Autopsy showed extensive polyglucosan body formation in many regions of the central nervous system, including the basal ganglia, thalamus, substantia nigra, and anterior horns (Figure 2) . In addition, numerous ␣-synuclein-staining Lewy bodies were observed in the substantia nigra, accompanied by neuronal depopulation. There were no Lewy bodies in the cortex.
COMMENT
Polyglucosan body disease is a rare heterogeneous disease affecting the central and peripheral nervous system. In most cases there is upper and lower motor neuron involvement, neurogenic bladder, and cortical or subcortical dementia.
1,2 Less common features include fecal incontinence, entrapment neuropathies, supranuclear gaze palsy, and skeletal and cardiac muscle dysfunction. 1, [3] [4] [5] Polyglucosan body disease is one of the few diseases that is seen with both upper and lower motor neuron signs and can simulate amyotrophic lateral sclerosis when sensory function is spared. 6 In most cases, however, there is early sensory loss in the lower limbs to help distinguish PGBD from amyotrophic lateral sclerosis. 1 Urinary incontinence is also a distinctive feature. The disease is inexorably progressive, and survival is variable (range, 1-20 years). 1, 5 Extrapyramidal features are rarely reported in PGBD. Robertsonetal 5 describeda50-year-oldwomanwithaspeech disturbance who 1 year later developed balance problems, resting tremor of the right hand, urinary urgency, and cognitive impairment. There was no response to apomorphine hydrochloride or oral levodopa treatment. They suggested that although extrapyramidal features could be explained by a second process, PGBD may be the primary cause given the rapid evolution of other neurologic symptoms and the known accumulation of polyglucosan bodies in the brain.
Diagnosis of PGBD is based on clinical findings and confirmed by the presence of intra-axonal polyglucosan bodies in peripheral nerve or brain at autopsy. In autopsy series, polyglucosan bodies were found in processes of neurons and astrocytes. 1 The polyglucosan bodies may also be present in cardiac and skeletal muscle, liver, and apocrine glands, suggesting a generalized storage disorder. [3] [4] [5] Polyglucosan bodies are small ellipsoid or threadlike structures, composed mainly of glucose polymers with phosphate and sulfate groups. They stain intensely on PAS preparations. Polyglucosan bodies are nonspecific and may be seen with aging, Lafora disease, type IV gly- cogenosis, axonal neuropathy, as well as PGBD. 1, 7 Therefore, the histological findings must be correlated with the clinical scenario.
The pathogenesis of PGBD remains uncertain. Some have proposed that the polyglucosan bodies interfere with axonal flow. In some patients of Jewish Ashkenazi descent who have PGBD, glycogen-branching enzyme (GBE) activity in leukocytes and peripheral nerve is reduced. 7, 8 Decreased GBE activity has also been reported in other adult patients with PGBD who were products of consanguineous marriages. Their offspring had partial GBE deficiency suggesting an autosomal recessive inheritance pattern. 9 MissensemutationsoftheGBEgenehavebeendetectedinPGBD, demonstrating that a subtype of the adult disease is allelic with type IV glycogenosis. 8 Other mutations of the GBE gene have also been found in non-Ashkenazi Jews indicating that this is not a disease affecting the Jewish population only. 10 Lewy bodies are neuronal intracytoplasmic inclusions that may be seen in Parkinson disease, diffuse Lewy body disease, autonomic failure, and Lewy body dysphagia. 11 A major component of the Lewy body is the protein ␣-synuclein. The absence of cortical Lewy bodies in our patient suggests that diffuse Lewy body disease is not the cause of her dementia. Although levodopa-reponsive tremor may be a rare feature of PGBD, the presence of Lewy bodies in our patient suggests that she had concomitant idiopathic Parkinson disease. We are unaware of any prior report of polyglucosan bodies and Lewy bodies in the same individual and are unable to link their formation to a common biochemical process. Likewise, any association between PGBD and Parkinson disease is speculative.
CONCLUSIONS
We present the first patient with PGBD who on autopsy was found to have polyglucosan as well as Lewy body formation in the substantia nigra. Her initial neurologic symptom was a levodopa-responsive tremor. Although extrapyramidal symptoms are rarely reported as a manifestation of PGBD, we suspect our patient's tremor was related to idiopathic Parkinson disease.
